<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        4-5197-20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        BICNU
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CARMUSTINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder and solvent for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        3743.45
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Emcure Pharmaceuticals Ltd. " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Emcure Pharmaceuticals Ltd. 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 416]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Arabian Health Care Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Emcure Pharmaceuticals Ltd. 
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01AD01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>BiCNU &nbsp;100 &nbsp;mg-Powder &nbsp;and &nbsp;solvent &nbsp;for &nbsp;solution &nbsp;for infusion &nbsp;is &nbsp;a &nbsp;medicine &nbsp;which &nbsp;contains &nbsp;<br />carmustine. Carmustine &nbsp;belongs &nbsp;to &nbsp;a &nbsp;group &nbsp;of &nbsp;anticancer substances known as nitrosourea that&nbsp;<br />act by slowing the growth of cancer cells.<br />BiCNU &nbsp;is &nbsp;used &nbsp;as &nbsp;palliative &nbsp;therapy &nbsp;(relieving &nbsp;and preventing the suffering of patients) as&nbsp;<br />a single agent or in &nbsp;established &nbsp;combination &nbsp;therapy &nbsp;with &nbsp;other approved &nbsp;anticancer &nbsp;<br />substances &nbsp;in &nbsp;certain &nbsp;types &nbsp;of cancers, like:<br />&bull; &nbsp;Brain tumours- glioblastoma, medulloblastoma, astrocytoma and metastatic brain tumours<br />&bull; &nbsp;Multiple myeloma (malignant tumour developing from bone marrow)<br />&bull; &nbsp;Hodgkin&#39;s disease (lymphoid tumour)<br />&bull; &nbsp;Non-Hodgkin&#39;s lymphomas (lymphoid tumour)<br />Children and adolescents:<br />- &nbsp;BiCNU must not be used in children and adolescents<br />aged less than 18 years.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use BICNU</strong>&nbsp;:</p><p>-&nbsp; if you are allergic to carmustine, other nitrosourea medicines or any of the other ingredients&nbsp;<br />of this medicine (listed in section 6).<br />BiCNU should not be used in patients who have reduced number of blood platelets (thrombocytes),&nbsp; white blood cells (leucocytes) &nbsp;or &nbsp;red &nbsp;blood &nbsp;cells &nbsp;(erythrocytes),&nbsp;either as a result of&nbsp; &nbsp;chemotherapy or from other causes.<br />- &nbsp;If you suffer from severe kidney function impairment<br />- &nbsp;If &nbsp;age &nbsp;of &nbsp;the &nbsp;patient is &nbsp;less &nbsp;than &nbsp;18 &nbsp;years &nbsp;of &nbsp;age<br />- &nbsp;If you are pregnant or a lactating mother<br /><strong>Warnings and precautions</strong><br />Talk to your doctor, pharmacist or nurse before using BiCNU.<br />Since the major side effect of this medicine is delayed bone marrow suppression, your doctor will&nbsp;<br />monitor blood counts weekly for at least 6 weeks after a dose. At the recommended dosage, courses&nbsp;<br />of BiCNU would not be &nbsp;given &nbsp;more &nbsp;frequently &nbsp;than &nbsp;every &nbsp;6 &nbsp;weeks. The dosage will be confirmed&nbsp;<br />with the blood count.<br />Inform your physician immediately if you experience any of the following symptoms:</p><ul><li>Signs of infection (fever, persistent sore throat)</li><li>Enhanced tendency to bruising/bleeding</li><li>Unusual tiredness</li><li>&nbsp;Accelerated/throbbing heartbeat</li></ul><p>Before treatment, your liver and kidney function will be tested and observed regularly during the&nbsp;<br />treatment.<br />Since the use of BiCNU can lead to lung damage, an X- ray of the chest region and &nbsp;the lung&nbsp;<br />function tests will be conducted (Please also see the section&ldquo;Possible side effects&rdquo;).<br />Your doctor will talk to you about the possibility of lung damage and allergic reactions and their&nbsp;<br />symptoms. If such symptoms occur, you should contact your doctor immediately (see section 4).<br /><strong>Other medicines and BiCNU</strong><br />Tell your doctor or pharmacist if you are taking, have recently &nbsp;taken &nbsp;or &nbsp;might &nbsp;take &nbsp;any &nbsp;other&nbsp;<br />&nbsp;medicines, including &nbsp;medicines &nbsp;obtained &nbsp;without &nbsp;prescription, such as:</p><ul><li>&nbsp;Phenytoin and phenobarbital used in epilepsy.</li><li>Cimetidine, used for stomach problems like indigestion.</li><li>Digoxin, used if you have abnormal heart rhythm</li><li>Melphalan, an anticancer drug</li><li>Dexamethasone, steroid-responsive conditions.</li><li>Methotrexate, cyclophosphamide, procarbazine, chlormethine (nitrogen mustard), fluorouracil, vinblastine, actinomycin (dactinomycin), bleomycin, doxorubicin (adriamycin)</li><li>ondansteron, used to prevent nausea and vomiting</li></ul><p><strong>Pregnancy, breast-feeding and fertility</strong><br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby,&nbsp;<br />ask your doctor &nbsp;or &nbsp;pharmacist &nbsp;for &nbsp;advice &nbsp;before &nbsp;taking &nbsp;this medicine.<br />&nbsp;</p><p><u>Pregnancy and fertility</u><br />BiCNU should not b used during pregnancy because it may harm your unborn baby. Therefore this&nbsp;<br />medicine should &nbsp;not &nbsp;normally &nbsp;be &nbsp;administered &nbsp;to &nbsp;pregnant women. If used during pregnancy, the&nbsp;<br />patient must be aware of the potential risk to the unborn baby. Women of &nbsp;childbearing &nbsp;potential &nbsp;<br />are &nbsp;advised &nbsp;to &nbsp;avoid becoming &nbsp;pregnant &nbsp;whilst &nbsp;being &nbsp;treated &nbsp;with &nbsp;this medicine.<br />Male &nbsp;patients &nbsp;should &nbsp;use &nbsp;adequate &nbsp;contraceptives measures during treatment with BiCNU for at&nbsp;<br />least 6 months to prevent their partners becoming pregnant.<br />The &nbsp;fertility &nbsp;of &nbsp;male &nbsp;patients &nbsp;may &nbsp;be &nbsp;affected &nbsp;by treatment &nbsp;with &nbsp;BiCNU. &nbsp;You &nbsp;should &nbsp;<br />seek &nbsp;adequate counselling regarding fertility/family planning before initiating treatment with&nbsp;<br />BiCNU.<br />Breast-feeding<br />You should not breast-feed while taking this medicine and up to seven days after completion of&nbsp;<br />treatment.<br /><strong>Driving and using machines</strong><br />The effect of this medicine on your ability to drive and use machines is not known. You must check&nbsp;<br />with your doctor &nbsp;before &nbsp;driving &nbsp;or &nbsp;operating &nbsp;any &nbsp;tools &nbsp;or machines &nbsp;because &nbsp;the &nbsp;amount &nbsp;of&nbsp;<br />&nbsp;alcohol &nbsp;in &nbsp;this medicine &nbsp;may &nbsp;impair &nbsp;your &nbsp;ability &nbsp;to &nbsp;drive &nbsp;or &nbsp;use machines.<br /><strong>BiCNU contains ethanol (alcohol)</strong><br />This &nbsp;medicinal &nbsp;product &nbsp;contains &nbsp;0.57 &nbsp;vol% &nbsp;ethanol (alcohol), &nbsp;which &nbsp;means &nbsp;7.68 &nbsp;g &nbsp;per &nbsp;<br />dose. &nbsp;This corresponds to 11.32 ml of beer or 4.72 ml wine, per dose. This may be harmful for those suffering<br />from alcoholism, liver disease or epilepsy (fits).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>BiCNU will always be given to you by a healthcare&nbsp; professional with experience in the use of anticancer agents.<br />This medication is for intravenous infusion.<br /><strong>Adults</strong><br />Dosage is based on your medical condition, body size and response to treatment. It is usually given&nbsp;<br />at least every 6 weeks. The recommended dose of BiCNU as a single agent in previously untreated&nbsp;<br />patients is 150 to 200 mg/m2 &nbsp;intravenously every 6 weeks. This may be given &nbsp;as &nbsp;a &nbsp;single &nbsp;dose &nbsp;<br />or &nbsp;divided &nbsp;into &nbsp;two &nbsp;daily injections such as 75 to 100 mg/m2 &nbsp;on two successive days. Dosage&nbsp;<br />will also depend on whether BiCNU is given with other anti-cancer drugs.</p><p>Doses will be adjusted according to how you respond to the treatment.</p><p>Your blood count will be monitored frequently to avoid toxicity in your bone marrow and the dose&nbsp; adjusted if necessary.</p><p><strong>Route of administration</strong><br />BiCNU is given into a vein by a drip over a one to two hour period. The time of infusion should not&nbsp;<br />be less than one hour to avoid burning and pain at the injected area. The &nbsp;injected &nbsp;area &nbsp;will &nbsp;be&nbsp;<br />&nbsp;monitored &nbsp;during &nbsp;the administration.</p><p>The duration of the treatment is determined by the doctor and may vary for each patient.</p><p><strong>Use in children and adolescents (age &lt;18 years)</strong></p><p>BiCNU&nbsp;cannot be used in children and adolescents due to high risk of lung toxicity.<br />&nbsp;</p><p><strong>Use in elderly</strong><br />BiCNU can be used with caution in elderly patients.</p><p>The kidney function will be carefully monitored.</p><p><br /><strong>If you use more BiCNU than you should:&nbsp;</strong><br />As a doctor or nurse will be giving you this medicine, it is unlikely that you will receive an&nbsp;<br />incorrect dose. Tell your doctor or nurse if you have any concerns about the amount of medicine&nbsp;<br />that you receive.<br />If you have any further questions on the use of this product, ask your doctor or pharmacist or nurse.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>Tell your doctor or nurse immediately if you notice any of the following:</strong><br />Any &nbsp;sudden &nbsp;wheeziness, &nbsp;difficulty &nbsp;in &nbsp;breathing, swelling &nbsp;of &nbsp;the &nbsp;eyelids, &nbsp;face &nbsp;or &nbsp;lips, &nbsp;rash &nbsp;or &nbsp;itching (especially affecting your whole body), and feeling you are going to faint. These&nbsp;may be signs of severe allergic reaction.<br /><strong>BiCNU may cause the following side effects:</strong><br /><strong>Very common</strong> (may affect more than 1 in 10 people)<br />&bull; &nbsp;Delayed myelosuppression (decrease in blood cells in bone marrow);<br />&bull; &nbsp;Ataxia &nbsp;(lack &nbsp;of &nbsp;voluntary &nbsp;coordination &nbsp;of &nbsp;muscle movements);<br />&bull; &nbsp;Dizziness;<br />&bull; &nbsp;Headache;<br />&bull; &nbsp;Transient redness in the eye, blurred vision, retinal bleeding;<br />&bull; &nbsp;Hypotension &nbsp;(fall &nbsp;in &nbsp;blood &nbsp;pressure) &nbsp;in &nbsp;high-dose therapy;<br />&bull; &nbsp;Phlebitis (inflammation of the veins);<br />&bull; &nbsp;Respiratory disorders (lung related disorders) with breathing problems;<br />&bull; &nbsp;Severe nausea and vomiting; beginning within 2-4 hours of administration and lasting&nbsp;<br />for 4-6 hours;<br />&bull; &nbsp;When used on the skin, inflammation of the skin (dermatitis)<br />&bull; &nbsp;Accidental &nbsp;contact &nbsp;with &nbsp;skin &nbsp;may &nbsp;cause &nbsp;transient hyperpigmentation &nbsp;(darkening &nbsp;<br />of &nbsp;an &nbsp;area &nbsp; &nbsp; &nbsp; &nbsp; of skin or nails)<br /><strong>Common</strong> (may affect up to 1 in 10 people)<br />&bull; &nbsp;Acute &nbsp;leukemias &nbsp;and &nbsp;bone &nbsp;marrow &nbsp;dysplasias (abnormal &nbsp;development &nbsp;of &nbsp;the &nbsp;bone &nbsp;<br />marrow) following long term use;<br />&bull; &nbsp;Anaemia (decrease in the amount of red blood cells in the blood);<br />&bull; &nbsp;Encephalopathy &nbsp;(disorder &nbsp;of &nbsp;brain) &nbsp;in &nbsp;high-dose therapy;<br />&bull; &nbsp;Anorexia;<br />&bull; &nbsp;Constipation;<br />&bull; &nbsp;Diarrhoea;<br />&bull; &nbsp;Inflammation of the mouth and lips;<br />&bull; &nbsp;Reversible liver toxicity in high-dose therapy, delayed up to 60 days after&nbsp;<br />administration. This can result in increased liver enzymes and bilirubin (detected by blood tests);<br />&bull; &nbsp;Alopecia (loss of hair);<br />&bull; &nbsp;Flushing of the skin;<br />&bull; &nbsp;Reactions on the injection site<br /><strong>Rare </strong>(may affect up to 1 in 1,000 people)<br />&bull; &nbsp;Veno-occlusive disease (progressive blockage of the veins) in high-dose therapy;<br />&bull; &nbsp;Breathing problems caused by interstitial fibrosis (with lower doses);<br />&bull; &nbsp;Kidney problems<br />&bull; &nbsp;Gynecomastia (breast growth in males)<br /><strong>Not known</strong> (frequency cannot be estimated from the available data)<br />&bull; &nbsp;Muscular pain;<br />&bull; &nbsp;Seizures (fits) including status epilepticus;<br />&bull; &nbsp;Tissue damage due to leakage in injection area;<br />&bull; &nbsp;Infertility;<br />&bull; &nbsp;BiCNU has been shown to adversely affect the development of unborn babies<br />&bull; &nbsp;Any signs of infection<br />&bull; &nbsp;Fast heartbeat, chest pain<br />&bull; &nbsp;Allergic reaction;<br />&bull; &nbsp;A decrease in renal volume, progressive accumulation of certain metabolic products in&nbsp;<br />the blood (azotemia) and kidney failure were observed after high cumulative doses and after&nbsp;<br />long-term treatment with BiCNU and other nitrosoureas. Renal damage was also observed after lower&nbsp;<br />total doses;<br />&bull; &nbsp;Bleeding in the digestive system tract<br /><strong>Reporting of side effects</strong><br />If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side<br />effects directly to The National Pharmacovigilance and Drug Safety Centre (NPC) as mentioned the detailed contacts in the end of this documents. . By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep &nbsp;this &nbsp;medicine &nbsp;out &nbsp;of &nbsp;the &nbsp;sight &nbsp;and &nbsp;reach &nbsp;of children.</p><p>Do not use this medicine after the expiry date which is stated on the label and carton after&nbsp;<br />statement &ldquo;can be used up to&#39;. The expiry date refers to the last day of that month.</p><p>This medicine will be stored by your doctor or health care professional.</p><p>The unopened vial of the dry drug must be stored in a refrigerator &nbsp;(2&deg;-8&deg;C). &nbsp;After reconstitution &nbsp;as recommended,</p><p>Carmustine is stable for 24 hours under refrigeration (2&deg;-8&deg;C) in a&nbsp;glass container and must be protected from light.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist or doctor&nbsp;<br />how to throw &nbsp;away &nbsp;medicines &nbsp;you &nbsp;no &nbsp;longer &nbsp;use. &nbsp;These measures will help protect the environment.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is carmustine.<br />Each vial contains 100 mg of carmustine. The other ingredients are, Powder: none, Solvent: Ethanol&nbsp;anhydrous.<br />One pack contains one vial with 100 mg of powder for concentrate for solution for infusion and one&nbsp;vial with 3 ml solvent.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Powder and solvent for concentrate for solution for infusion.Pale yellow powder for reconstitution. 
Appearance of solution: colourless to light yellow Powder: Type I amber glass vial (30 ml) with a dark
grey bromo butyl rubber stopper and sealed with a polypropylene cap.

Solvent: Type I clear glass vial (5 ml) with a grey bromo butyl rubber stopper and sealed with a 
polypropylene cap.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><u>Marketing Authorisation Holder</u><br />Emcure Pharmaceuticals Limited (Oncology Division)<br />Plot no. P 2, I.T.B.T Park,<br />Phase II, MIDC, Hinjawadi, Pune, India<br /><u>Manufacturer</u><br />Emcure Pharmaceuticals Limited (Oncology Division)<br />Plot no. P 2, I.T.B.T Park,<br />Phase II, MIDC, Hinjawadi, Pune, India<br />To report any side effect(s):<br /><strong>&bull; Saudi Arabia:</strong></p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p>The National Pharmacovigilance Centre (NPC):<br />Fax: +966-11-205-7662<br />SFDA Call Center: 19999</p><p>E-mail:&nbsp;npc.drug@sfda.gov.sa<br />Website:&nbsp;https://ade.sfda.gov.sa/</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p><strong>This is a Medicament</strong></p><ul><li>Medicament is a product which affects your&nbsp;health and its consumption contrary to&nbsp;instructions is dangerous for you.</li><li>Follow strictly the doctor&#39;s prescription, the&nbsp;method of use and the instructions of the&nbsp;pharmacist who sold the medicament.</li><li>The doctor and the pharmacist are the experts in&nbsp;medicines, their benefits and risks.</li><li>Do not by yourself interrupt the period of&nbsp;treatment prescribed for you.</li><li>Do not repeat the same prescription without&nbsp;consulting your doctor.</li><li>Keep all medicaments out of reach of children<strong>.</strong></li></ul><p style="text-align:right"><strong>Council of Arab Health Ministers<br />Union of Arab Pharmacists</strong></p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 6/2023

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يحتوي بكنو على عقار كارموستين والذي ينتمي إلى مجموعة من الأدوية المضادة للسرطان تسمى نتروزويويا والتي تعمل على تقليل معدل نمو الخلايا السرطانية.<br />يستخدم بكنو كعلاج ملطف (لتخفيف ومنع معاناة المرضى) كعامل وحيد أو كعلاج مساعد مع الأدوية الأخرى المضادة للسرطان المعتمدة وذلك في حالات معينة من السرطان مثل:</p><p>أورام المخ- ورم أرومي، نخاعي، ورم نجمي وأورام الدماغ المنتشرة.</p><p>المايلوما المتعددة (ورم خبيث يصيب نخاع العظام).</p><p>داء هودجكن (سرطان الأنسجة اللمفاوية).</p><p>الأطفال والمراهقون:<br />يجب ألا تستخدم بكنو في الأطفال والمراهقين الذين تقل أعمارهم عن 18سنة&nbsp;<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تقم باستعمال بكنو:</p><p>إذا كان لديك حساسية (فرط الحساسية) لمادة كارموستين وغيرها من الأدوية المنتمية إلى مجموعة نتروزويويا وأي من المكونات الأخرى لمستحضر بكنو (أنظر إلى قسم 6).</p><p>لا ينبغي استخدام بكنو للمرضى الذين يعانون من انخفاض عدد الصفائح الدموية،&nbsp;وخلايا الدم البيضاء (الكريات البيضاء) أو خلايا الدم الحمراء (كرات الدم الحمراء)، إما نتيجة للعلاج الكيميائي أو لأسباب أخرى.<br />اذا كنت تعاني من ضعف شديد في وظائف الكلى<br />-اذا كان عمرالمريض اقل من ١٨ عاما<br />-اذا كنت حاملا او ام مرضعة</p><p>الاحتياطات والتحذيرات:&nbsp;<br />تحقق مع الطبيب أو الصيدلي قبل استخدام هذا الدواء في الحالات التالية:<br />بما أن التأثير الجانبي الرئيسي لهذا الدواء يتسبب في تأخير نخاع العظم، فإن طبيبك سيراقب مكونات الدم أسبوعيا لمدة 6 أسابيع على الأقل بعد تناول الجرعة. فالجرعة الموصي بها، لن تعطى على فترات أكثر من كل 6 أسابيع. وسوف يتم اعتماد الجرعة على أساس اختبارات مكونات الدم.<br />أخبر طبيبك فورا إذا واجهت أيًا من الأعراض التالية:<br />-علامات العدوى(الحمى والتهاب الحلق المستمر)&nbsp;<br />-تعزيز الميل إلى حدوث كدمات / نزيف<br />- التعب غير المعتاد<br />-تسارع / نبض ضربات القلب<br />وسيتم اختبار وظائف الكبد ووظائف الكلى قبل بدء العلاج، وسيتم مراقبتها بانتظام أثناء فترة العلاج.<br />حيث أن العلاج بتناول بكنو ممكن أن يؤدي إلى تلف الرئة، سيتم إجراء أشعة سينية لمنطقة الصدر واختبارات وظائف الرئة (الرجاء أيضا مراجعة قسم &quot;الاثار الجانبية المحتملة&quot;).<br />سوف يتحدث إليك طبيبك عن احتمالية حدوث تلف للرئة والحساسية وأعراضها. وفي حالة حدوث مثل هذه الأعراض، يجب عليك الاتصال بطبيبك على الفور (انظر القسم 4).<br />تناول الأدوية الأخرى مع بكنو&nbsp;<br />الرجاء إعلام الطبيب المعالج أو الصيدلي إذا كنت تستعمل أو استعملت أية أدوية أخرى مؤخرًا، بما في ذلك الأدوية التي تم استعمالها دون وصفة طبية. مثل:</p><p>الفينيتوين و الفينوبربيتال&nbsp;وتستخدم في علاج الصرع.&nbsp;</p><p>سيميتيدين، وتستخدم لعلاج مشاكل المعدة مثل عسر الهضم.</p><p>ديجوكسين، وتستخدم إذا كان لديك عدم انتظام في ضربات القلب.</p><p>ملفلان، وهو دواء مضاد للسرطان.</p><p>ديكساميثازون ، ظروف تستجيب الستيرويد</p><p>-ميثوتريكسات ، سيكلوفوسفاميد ، بروكاربازين ، كلورثين (نيتروجين مسترد) ، فلورويوراسيل ،فينبلاستين ، أكتينوميسين&nbsp;</p><p>(داكتينومايسين) ، بليوميسين ، دوكسوروبيسين (أدريامايسين)</p><p>أوندانستيرون ، الذي يستعمل للوقاية من الغثيان والقيء</p><p>الحمل والرضاعة الطبيعية والخصوبة<br />وسائل منع الحمل في النساء اللاتي يتناولن بكنو<br />يجب التحدث مع طبيبك قبل تناول بكنو إذا كنت حاملا أو من الممكن أن تصبح حاملا أو بصدد التخطيط للحمل أو أثناء الرضاعة الطبيعية.<br />الحمل والخصوبة<br />لا ينبغي استخدام بكنو خلال فترة الجمل لأنه قد يؤذي الجنين. لذلك لا ينبغي أن يوصف هذا الدواء للنساء الحوامل. في حالة الاستعمال خلال فترة الحمل، يجب أن يكون المريض على بينة من المخاطر المحتملة على الجنين.<br />ينصح النساء اللاتي لديهن القدرة على الحمل تجنب الحمل أثناء فترة العلاج. يُنصح النساء اللاتي لديهنّ القدرة على الحمل أن يستخدمن وسائل منع الحمل الفعّالة لتجنّب الحمل أثناء العلاج ولمدّة 6 أشهر على الأقل بعد العلاج.&nbsp;<br />وينبغي على المرضى الذكور أخذ التدابير الكافية باستخدام وسائل منع الحمل خلال فترة العلاج مع بكنو ولمدة ٦ أشهر على الأقل لمنع شريكته&nbsp;من أن تصبح حاملاً.&nbsp;</p><p><br />الرضاعة الطبيعية<br />لا يجب الرضاعة الطبيعية أثناء تناول هذا الدواء وبعد سبعة أيام بعد الانتهاء &nbsp;من العلاج.</p><p>القيادة واستخدام الآلات:&nbsp;<br />تأثير هذا الدواء على قدرتك على القيادة واستخدام الآلات غير معروف. يجب عليك مراجعة طبيبك قبل القيادة أو تشغيل أي أدوات أو الات لأن كمية الكحول في هذا الدواء قد تضعف قدرتك على القيادة أو استخدام الآلات.<br />يحتوي بكنو على الإيثانول (كحول لا مائي)<br />يحتوي هذا المنتج الطبي على 0.57% حجم من الإيثانول (كحول لا مائي)، وهو يعني 7.68جم لكل جرعة. والذي يمثل 11.32مل من البيرة أو 4.72 مل خمر ولكل جرعة. وهذا يكون ضار للأشخاص الذين يعانون من التسمم الكحولي، وأمراض الكبد أو نوبات الصرع.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>طريقة تناول بكنو&nbsp;<br />يجب أن يقوم طبيب مختص من ذوي الخبرة في استخدام العوامل المضادة للسرطان بالإشراف على استخدام بكنو.<br />يتمّ تناول هذا الدواء عن طريق التسريب الوريدي.&nbsp;</p><p>الكبار</p><p>تختلف الجرعة الخاصة بك باختلاف حالتك الصحية، وحجم واستجابة الجسم للعلاج. وعادة ما يتم تناوله على الأقل كل 6 أسابيع. الجرعة الموصي بها حينما يتم استخدام بكنو كعامل وحيد في علاج المرضى الذين لم يسبق لهم العلاج هي 150-200ملجم/م2 بالحقن في الوريد كل 6أسابيع. ومن الممكن أن تعطى هذه كجرعة واحدة أو مقسمة إلى قسمين حقنة يومية مثل 75-100ملجم/م2 على يومين متتاليين. وتعتمد الجرعة أيضا على ما إذا كان يتم تناول تكنو مع أدوية أخرى مضادة للسرطان.</p><p>يتم تعديل الجرعات وفقا لمدى استجابتك للعلاج.</p><p>وسيتم متابعة مكونات الدم بشكل متكرر لتجنب حدوث سمية في نخاع العظم وإذا لزم الأمر يتم تعديل الجرعة.</p><p>طريقة تناول الدواء</p><p>يتم تناول بكنو عن طريق التنقيط في الوريد لمدة أكثر من ساعة أو ساعتين. لا ينبغي أن يكون فترة التنقيط في الوريد أقل من ساعة واحدة لتجنب حدوث حرقان وألم في المنطقة التي يتم الحقن فيها. وسيتم ملاحظة المنطقة التي يتم الحقن فيها خلال فترة العلاج.</p><p>يتم تحديد مدة العلاج من قبل الطبيب وقد تختلف من مريض لآخر.</p><p>الاستخدام في الأطفال والمراهقين(عمر&gt;18سنة)</p><p>لا يمكن استخدام بكنو في الأطفال والمراهقين بسبب ارتفاع مخاطر سمية الرئة.</p><p>الاستخدام في كبار السن</p><p>يمكن أن تستخدم بكنو بحذر في المرضى المسنين. على أن يتم مراقبة وظائف الكلى بعناية.</p><p>الجرعة الزائدة من بكنو:</p><p>على الرغم من أنه يجب أن يقوم طبيب أو ممرضة بإعطائك هذا الدواء، فإنه من غير المحتمل تتلقى جرعة غير صحيحة. أخبر طبيبك أو الممرضة إذا كان لديك أية مخاوف حول كمية الدواء التي تتلقاها.</p><p>إذا كان لديك أي أسئلة أخرى عن استخدام هذا المنتج، اسأل الطبيب أو الصيدلي.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية، يمكن أن يتسبب بكنو في اثار جانبية، على الرغم من أنها لا تؤثر في الجميع.<br />أخبر الطبيب على الفور حيث قد تحتاج إلى عناية طبية عاجلة إذا كنت تواجه أي من الأعراض التالية:<br />حالات الأزيز المفاجئ، وصعوبة في التنفس، تورم في الجفون والوجه أو الشفاه، طفح جلدي أو حكة (خاصة التي تؤثر على الجسم كله)، والشعور بالوهن. قد تكون هذه علامات لحساسية شديدة.</p><p>قد يسبب تناول بكنو في الأعراض الجانبية التالية:<br /><strong>أعراض جانبية شائعة جدا:</strong> (أكثر من مريض من أصل 10)</p><ul><li>تثبيط نقي العظم (نقص خلايا الدم في نخاع العظام).</li><li>&nbsp;رنح (فقد انتظام حركات العضلات).</li><li>دوخة.</li><li>&nbsp;صداع الرأس.</li><li>احمرار مؤقت في العين، عدم وضوح الرؤية، ونزيف في شبكية العين.</li><li>&nbsp;انخفاض ضغط الدم (فشل في ضغط الدم) في حالة تناول جرعة عالية.</li><li>&nbsp;الالتهاب الوريدي (التهاب الأوردة).</li><li>اضطرابات الجهاز التنفسي (اضطرابات ذات الصلة بالرئة) مصطحبة بمشاكل في التنفس.</li><li>&nbsp;الغثيان الشديد والقيء. يبدأ خلال 2-4 ساعات من الاستخدام ويمتد لمدة 6-4 ساعات.</li><li>عندما يستخدم على الجلد، يتسبب في التهاب الجلد (أكزيما).</li><li>تعرض الجلد للدواء بشكل غير مقصود قد يسبب فرط تصبغ مؤقت (مساحة الجلد أو الأظافر المعرضة يصبح لونها غامق)</li></ul><p><strong>أعراض جانبية شائعة:</strong> (أكثر من مريض من أصل 10)</p><ul><li>اللوكيميا الحادة وخلل نمو نخاع العظم (نمو غير طبيعي لنخاع العظام) بعد استخدام العلاج على المدى الطويل.</li><li>فقر الدم (نقص كمية خلايا الدم الحمراء في الدم).</li><li>اعتلال دماغي (اضطراب في الدماغ) في الجرعات العالية.</li><li>فقدان الشهية.</li><li>الإمساك.</li><li>إسهال.</li><li>التهاب الفم والشفتين.</li><li>تسمم كبدي يعود مرة أخرى في العلاج بجرعة عالية، ويتأخر إلى 60 يوما بعد تناوله. وهكذا يمكن أن يؤدي إلى زيادة إنزيمات الكبد والبيليروبين (يتم الكشف عنها بواسطة اختبارات الدم).</li><li>ثعلبة (تساقط الشعر)</li><li>طفح جلدي.</li><li>التهابات في موقع الحقن.</li></ul><p><strong>أعراض جانبية نادرة:</strong> (ما يصل إلى مريض من أصل 1000)</p><ul><li>مرض الانسداد الوريدي (انسداد تدريجي للشرايين) في الجرعة عالية.</li><li>&nbsp;مشاكل التنفس الناجمة عن التليف الخلالي (مع الجرعات المنخفضة).</li><li>مشاكل في الكلى&nbsp;</li><li>التثدي (نمو الثدي عند الذكور)</li></ul><p><strong>أعراض جانبية غير معلومة</strong>: (لا يمكن تقدير معدلها من البيانات المتوفرة)</p><ul><li>&nbsp;ألم عضلي.</li><li>&nbsp;نوبات صرع (نوبات) بما في ذلك حالة صرعية.</li><li>تلف الأنسجة نتيجة لتسرب في منطقة الحقن.</li><li>&nbsp;العقم.</li><li>قد تبين أن بكنو أن تؤثر سلبا على نمو الأجنة</li><li>أي علامات العدوى&nbsp;</li><li>ضربات قلب سريعة</li><li>ألم في الصدر</li><li>رد فعل تحسسي.</li><li>انخفاض في حجم الكلى وتراكم تدريجي لبعض منتجات التمثيل الغذائي في الدم (آزوتيميا) والفشل الكلوي بعد الجرعات التراكمية العالية وبعد العلاج طويل الأمد مع بيكنو وغيرها من نتروزويويا.لوحظ تلف الكلى أيضًا بعد الجرعات الإجمالية المنخفضة ؛</li><li>نزيف في الجهاز الهضمي</li></ul><p><strong>الإبلاغ عن الآثار الجانبية</strong>:</p><p>إذا زادت حدة أي من هذه الأعراض الجانبية، أو لاحظت ظهور أعراض جانبية غير ما تم ذكره في هذه النشرة، يرجى إبلاغ الطبيب المعالج أو الصيدلي. يمكنك أيضًا الإبلاغ عن الآثار<br />الجانبية مباشرة مباشرة عبر نظام الإبلاغ الوطني المُدرج في نهاية هذه النشرة.من خلال تسجيل تقارير الاثار الجانبية يمكن أن تساعد في توفير مزيد من المعلومات حول سلامة هذا الدواء..</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>كيفية تخزين بكنو</p><p>يحفظ بعيدًا عن متناول أيدي الأطفال أو على مرأى منهم.</p><p>لا تستخدم بكنو بعد انتهاء تاريخ الصلاحية المذكور على العبوة الخارجية. تاريخ انتهاء الصلاحية يشير إلى اليوم الأخير من ذلك الشهر.</p><p>&nbsp;سيتم تخزين هذا الدواء عن طريق الطبيب أو اخصائي الرعاية الصحية.</p><p>يجب أن يتم تخزين القارورة المغلقة والمحتوية على المسحوق الجاف في الثلاجة (2&deg; &ndash;8&deg;) بعد حل الدواء على النحو الموصي به، فإن المحلول سيصبح ثابت لمدة 24 ساعة تحت التبريد (2&deg; &ndash;8&deg;) في وعاء زجاجي ويجب أن تكون محمية من الضوء.</p><p>لا ينبغي أن يتم التخلص من الأدوية في مياه الصرف الصحي أو عن طريق النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد مطلوبة. هذه التدابير تساعد في الحفاظ على البيئة.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;<br />المادة الفعالة هي كارموستين.</p><p>قارورة سعة ٣٠ مل تحتوي على ۱٠٠ ملجم كارموستين وقارورة<br />أخرى سعة ٥مل تحتوي على ٣مل مخفف معقم (كحول لا مائي).<br />.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>مسحوق ومخفف للحقن في الوريد.<br />أصفر، رقيقة، رقائق هشة متقطعة أو كتلة متحجرة معدة للحل في المخفف.<br /><strong>شكل المحلول:</strong> عديم اللون إلى الأصفر الخفيف<br /><strong>مسحوق:</strong> قارورة زجاجية من الدرجة الأولى معتمة سعة ٣٠ مل مغطاه بسدادة مطاطية رمادية معتمة من بروموبيوتيل ومحكمة<br />بغطاء الألومنيوم ومغلفة بأمان بشريط من مادة البولي بروبيلين.<br /><strong>المخفف</strong>: قارورة زجاجية من الدرجة الأولى سعة ٥ مل مغطاه بسدادة مطاطية رمادية معتمة من بروموبيوتيل ومحكمة بغطاء<br />الألومنيوم ومغلفة بأمان بشريط من مادة البولي بروبيلين.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>مالك حق التسويق:</strong><br />شركة إمكيور للصناعات الدوائية المحدودة.<br />تي، بارك. p أي. تى. بى. تى، قطعة أرض رقم 2<br />. المرحلة الثانية، ام، أي، دي ، سى.، هينجوادي. بونا - ٤۱۱٠٥۷<br />ولاية ماهاراشترا، الهند</p><p><strong>الشركة المصنعة:</strong><br />شركة إمكيور للصناعات الدوائية المحدودة.<br />تي، بارك. p أي. تى. بى. تى، قطعة أرض رقم 2<br />. المرحلة الثانية، ام، أي، دي ، سى.، هينجوادي. بونا - ٤۱۱٠٥۷<br />ولاية ماهاراشترا، الهند</p><p><strong>للإبلاغ عن أيه آثار جانبية:</strong></p><p><u>المملكة العربيه السعودية</u><strong>:&nbsp;</strong></p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p>المركز الوطني للتيقظ الدوائي</p><p dir="ltr">+966-11-205- رقم الفاكس : 7662<br />مركز الاتصال الموحد: 19999<br />npc.drug@sfda.gov.sa: - البرید الالكتروني<br />https://ade.sfda.gov.sa/: الموقع الالكتر</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p style="text-align:center"><strong>إنّ هذا الدّواء</strong></p><ul><li dir="rtl">قد یُؤثر الدَّواء على صحتك إذا استخدمته على نحو</li></ul><p>&nbsp;مخالف للتعليمات مما قد يعرضك للإصابة بخطر.</p><ul><li>اتبع بدقة وصفة الطبيب المعالج لك وطریقة الاستعمال &middot;</li></ul><p>المنصوص عليھا وتعليمات الصيدلي الخاص بك الذي<br />صرف الدواء لك.</p><ul><li>الطبيب المعالج لك والصيدلي الخاص بك ھما الخبيران &middot;</li></ul><p>بالدواء وبنفعه وضرره.</p><ul><li>لا توقف فترة العلاج التي تم وصفھا لك من تلقاء نفسك. &middot;</li><li>لا تكرر هذا الدواء دون استشارة الطبيب المعالج لك. &middot;</li><li>تحفظ الأدویة بعيدًا عن متناول الأطفال. &middot;</li></ul><p style="text-align:left"><strong>مجلس وزراء الصحة العرب<br />اتحاد الصيادلة العرب</strong></p></td></tr></tbody></table><p><br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
             تم الموافقة على هذه النشرة بتاريخ 6/2023 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                BiCNU 100 mg powder and solvent for concentrate for solution for infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each vial of powder for concentrate for solution for infusion contains 100 mg
carmustine.
After reconstitution and dilution (see section 6.6), one mL of solution contains 3.3 mg
carmustine.
Excipient with known effect
Each vial of solvent contains 3 ml anhydrous ethanol (equivalent to 2.37 g).
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder and solvent for concentrate for solution for infusion.
Pale yellow powder. Carmustine appears with small quantities of dried flakes or as a
dry rigid mass.
Clear, colourless solvent
Appearance of solution: colourless to light yellow
pH: 4.0 to 6.8 (of the powder)
The osmolarity of the solution for infusion that is reconstituted with dehydrated
ethanol and sterilized water is 15.6 mOsmol/l. The solution for infusion that is diluted
with physiological saline or with 5% glucose solution is isotonic with the plasma.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Carmustine &nbsp;is &nbsp;indicated &nbsp;as &nbsp;palliative &nbsp;therapy &nbsp;as &nbsp;a &nbsp;single &nbsp;agent &nbsp;or &nbsp;in &nbsp;established&nbsp;combination therapy with other approved chemotherapeutic agents in the following:<br />&bull; &nbsp; &nbsp; Brain &nbsp; &nbsp; &nbsp;tumours &nbsp; &nbsp; &nbsp;- &nbsp; &nbsp; &nbsp;glioblastoma, &nbsp; &nbsp; &nbsp;Brain-stem &nbsp; &nbsp; &nbsp;gliomas, &nbsp; &nbsp; &nbsp;<br />ependymoma medulloblastoma, astrocytoma and metastatic brain tumours.<br />&bull; &nbsp; &nbsp; Multiple myeloma - in combination with glucocorticoid such as prednisone.<br />&bull; &nbsp; &nbsp; Hodgkin&rsquo;s &nbsp;disease &nbsp;- &nbsp;as &nbsp;secondary &nbsp;therapy &nbsp;in &nbsp;combination &nbsp;with &nbsp;other &nbsp;<br />approved drugs in patients who relapse while being treated with primary therapy, or whfoail to&nbsp;<br />respond to primary therapy.<br />&bull; &nbsp; &nbsp; Non-Hodgkin&rsquo;s &nbsp;lymphomas &nbsp;- &nbsp;as &nbsp;secondary &nbsp;therapy &nbsp;in &nbsp;combination &nbsp;with &nbsp;other&nbsp;<br />approved drugs in patients who relapse while being treated with primary therapyo, r who fail to&nbsp;<br />respond to primary therapy.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>BiCNU</u> must be administered only by specialists experienced in the field of chemotherapy and under appropriate medical supervision.<br />Posology<br /><u>Initial doses</u><br />The recommended dose of Carmustine as a single agent in previously untreated patients is 150 to 200 mg/m2 intravenously every 6 weeks. This may be given as a single dose or divided into daily injections such as 75 to 100 mg/m2 on two successive days.<br />When Carmustine is used in combination with other myelosuppressive medicinal products or in patients in whom bone marrow reserve is depleted, the doses should be adjusted according to the haematologic profile of the patient as shown below.<br /><u>Monitoring and subsequent doses</u><br />A repeat course of Carmustine should not be given until circulating blood elements have returned to acceptable levels (platelets above 100,000/ mm3, leukocytes above 4,000/ mm3), and this is usually in six weeks. Blood counts should be monitored frequently and repeat courses should not be given before six weeks because of delayed hematologic toxicity.<br />Doses subsequent to the initial dose should be adjusted according to the hematologic response of the patient to the preceding dose, in both monotherapy as well as in combination therapy with other myelosuppressive medicinal products. The following schedule is suggested as a guide to dosage adjustment:<br />Table 1</p><p>In cases where the nadir after initial dose does not fall in the same row for leucocytes and platelets (e.g. leucocytes &gt;4,000 and platelets &lt;25,000) the value given the lowest percentage of prior dose should be used (e.g. platelets &lt;25,000 then a maximum of 50% of prior dose should be given).<br />Special populations Elderly<br />In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dose range, reflecting the greater frequency of decreased hepatic,<br />renal, or cardiac function, and of concomitant disease or other therapy with other medicinal productsBecause elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and renal function should be monitored and the dose reduced according to this.</p><p>Paediatric population<br />Carmustine is contraindicated in children and adolescents aged &lt;18 years (see section 4.3) due to the high risk of pulmonary toxicity (see Section 4.4).<br /><u>Renal impairment<br />For patients with renal impairment the dose of Carmustine should be reduced if the glomerular filtration rate is reduced.</u></p><p><u>Method of administration:</u><br />Carmustine is for intravenous use after reconstitution and further dilution.<br />Following reconstitution (see section 6.6) with the sterile solvent provided (3 ml vial) and sterile water for injection, and further dilution with 500 ml with sodium chloride<br />9 mg/ml (0.9%) solution for injection, or 500 ml with 5% glucose solution for injection, carmustine should be administered immediately by intravenous drip over one- to two-hour period. The duration of infusion should not be less than one hour, otherwise it leads to burning and pain in the injected area. The injected area should be monitored during the administration.<br />There are no limits for the period of application of carmustine therapy. In case the tumour remains incurable or some serious or intolerable side effects appear, the carmustine therapy must be terminated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance, to other nitrosoureas or to any of the excipients listed in section 6.1.
Severe bone marrow depression or myelosuppression. 
Severe (end-stage) renal impairment.
Children and adolescents. 
Pregnancy and breast-feeding.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pulmonary toxicity characterised by pulmonary infiltrates and/or fibrosis has been reported to occur with a frequency ranging up to 30%. This may occur within 3 years of therapy and appears to be dose related with cumulative doses of 1200-1500 mg/m2 being associated with increased likelihood of lung fibrosis. Risk factors include smoking, the presence of a respiratory condition, pre-existing radiographic abnormalities, sequential or concomitant thoracic irradiation and association with other agents that cause lung damage. Baseline pulmonary function studies and chest<br />&nbsp;<br />X-ray should be conducted along with frequent pulmonary function tests during treatment. Patients with a baseline below 70% of the predicted forced vital capacity (FVC) or carbon monoxide diffusing capacity (DLCO) are particularly at risk.<br />Hepatic and renal function should also be checked prior to treatment and regularly monitored during therapy (see section 4.8).<br />Carmustine is carcinogenic in rats and mice at doses less than the recommended human dose based on body surface area.<br />Bone marrow toxicity<br />Delayed and cumulative bone marrow toxicity is a common and severe toxic adverse reaction of Carmustine. Complete blood count should be monitored frequently for at least six weeks after a dose. In case of a decreased number of circulating platelets, leucocytes or erythrocytes either from previous chemotherapy or other cause the dose should be adjusted, see Table 1, section 4.2.In addition to this, the liver, kidney and lung function should be examined and monitored regularly during the carmustine therapy (see section 4.8). Repeat doses of Carmustine should not to be given more frequently than every six weeks.<br />The bone marrow toxicity of Carmustine is cumulative and therefore the dosage adjustment must be considered on the basis of nadir blood counts from prior dose (see section 4.2).<br /><u>Alcohol</u><br />This medicinal product contains 0.57 vol% ethanol (alcohol), i.e. up to 7.68 g per dose, equivalent to 11.32 ml of beer or 4.72 ml wine per dose.<br />These amounts arise from a calculated example with 320 mg of carmustine (200 mg/m2 for 1.6 m2) dissolved in 9.6 ml (sterile dehydrated ethanol) and a volume of 1696 ml (see section 6.6).<br />For patients addicted to alcohol, this quantity can be harmful to health.<br />This must be considered in pregnant and breast-feeding women as well as in high-risk groups (patients with liver disease or epilepsy).<br />The alcohol content in this medicinal product may alter the effects of other drugs, and may impair the ability to drive and to use machines.<br />Parenteral administration<br />The intra-arterial compatibility has not been tested. Severe tissue damage can be expected in case of inadvertent intra-arterial administration.<br />Experimental direct injection of Carmustine to the carotid artery has been associated with ocular toxicity.<br />During administration of carmustine, administration site reactions may occur (see section 4.8). Given the possibility of extravasation, close monitoring of the infusion site is recommended for possible infiltration during administration. A special method for handling extravasation is currently unknown.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Dexamethasone</u></p><p>In combination with chemotherapeutic medicinal products reduced activity of antiepileptic medicinal products must be anticipated.</p><p><u>Phenytoin&nbsp;</u><br />BiCNU when coadministered with phenytoin may reduce phenytoin serum concentrations. Consider alternative drugs to phenytoin.</p><p><u>Phenobarbital</u><br />Phenobarbital induces the metabolism of carmustine and may compromise antitumor activity of BiCNU. Consider alternative drugs to phenobarbital.<br /><u>Cimetidine</u><br />Concomitant use leads to delayed, major, suspected, increased carmustine toxic effect (due to the inhibition of carmustine metabolism) or increased myelotoxicity (e.g. leukopenia and neutropenia)</p><p><u>Chemotherapy</u><br />Carmustine do not affect the pharmacokinetics of ondansetron.<br /><u>Digoxin</u><br />Concomitant use leads to delayed, moderate, suspected, decreased effect of digoxin (due to the decreased digoxin absorption)<br /><u>Melphalan</u><br />Concomitant use leads to increased risk of pulmonary toxicity<br />Thrombopenia and leukopenia can be expected when combined with other myelosuppressive drugs, e.g. Methotrexate, cyclophosphamide, procarbazine, chlormethine (nitrogen mustard), fluorouracil, vinblastine, actinomycin (dactinomycin), bleomycin, doxorubicin (adriamycin) - or in patients whose bone marrow reserve is depleted due to the disease itself or previous therapy<br />There is a possibility of cross resistance with other alkylating substances, e.g. Chloromethine and cyclophosphamide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential/contraception in males and females</u><br />Women of childbearing potential should use effective contraception to avoid becoming pregnant while on treatment and for at least 6 months after treatment.<br />Male patients should be advised to use adequate contraceptive measures during the treatment with carmustine and for at least 6 months after treatment.<br /><u>Pregnancy</u><br />Carmustine should not be administered to patients who are pregnant.<br />Safe use in pregnancy has not been established and therefore the benefit to risk of toxicity must be carefully weighed. Carmustine is embryotoxic in rats and rabbits and teratogenic in rats when given in doses equivalent to the human dose. If carmustine is used during pregnancy, or if the patient becomes pregnant while taking (receiving) carmustine, the patient should be apprised of the potential hazard to the fetus.<br /><u>Breast-feeding</u><br />It is unknown whether carmustine/metabolites are excreted in human milk. A risk to the newborns/infants cannot be excluded.<br />BiCNU is contraindicated during breast-feeding and up to seven days post-treatment (see section 4.3).<br /><u>Fertility</u><br />Carmustine may impair male fertility. Males should be advised of potential risk of infertility and to seek fertility/family planning counselling prior to therapy with carmustine.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies have been undertaken on the consequences the medicine on the competency to drive and the ability to operate machines.</p><p>However the possibility will have to be taken into consideration, that the alcohol quantity in these pharmaceutical medicines can impair the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>The table includes adverse events that were presented during drug treatment but may not necessarily have a causal relationship with the drug. Because clinical trials are conducted under very specific conditions, the adverse event rates observed may not reflect the rates observed in clinical practice. Adverse events are generally included if they were reported in more than 1% of patients in the product monograph or pivotal trials, and/or determined to be clinically important. When placebo-controlled trials are available, adverse events are included if the incidence is <u>&gt; </u>5% higher in the treatment group.</p><p>High dose is defined as &gt;200 mg/m<sup>2</sup></p><p>&nbsp;</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>The following table includes adverse reactions of carmustine listed by MedDRA system organ class and frequency convention presented in order of decreasing seriousness: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt; 1/1,000); very rare (&lt;1/10,000), not known (frequency cannot be estimated from the available data).</p><p>Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>MedDRA class</strong></p></td><td style="vertical-align:top"><p><strong>system</strong></p></td><td style="vertical-align:top"><p><strong>organ</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td colspan="4" style="vertical-align:top"><p><strong>Adverse reactions</strong></p></td></tr><tr><td colspan="8" style="vertical-align:top"><p>Clinically important side effects are in <em>italics</em></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Infections and Infestations</p></td><td style="vertical-align:top"><p>Unknown</p></td><td style="vertical-align:top"><p>Opportunistic</p><p>outcome)</p></td><td style="vertical-align:top"><p>infections</p></td><td style="vertical-align:top"><p>(including</p></td><td style="vertical-align:top"><p>fatal</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Neoplasms benign, malignant and unspecified (including</p><p>cysts and polyps)</p></td><td style="vertical-align:top"><p>common</p></td><td colspan="4" style="vertical-align:top"><p>Acute leukemias, bone marrow dysplasias; following long-term use.</p></td></tr><tr><td colspan="3" rowspan="2" style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>common</p></td><td colspan="4" style="vertical-align:top"><p>Anaemia.</p></td></tr><tr><td style="vertical-align:top"><p>very common</p></td><td colspan="4" style="vertical-align:top"><p><em>Myelosuppression; onset 7-14 days, nadir 21-</em></p><p><em>35 days, recovery 42-56 days; cumulative, dose related, delayed and often biphasic.</em></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>not known</p></td><td colspan="4" style="vertical-align:top"><p>Allergic reaction</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>MedDRA&nbsp;&nbsp;&nbsp; system&nbsp;&nbsp;&nbsp; organ class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reactions</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Clinically important side effects are in <em>italics</em></p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>very common</p></td><td style="vertical-align:top"><p>Ataxia, dizziness, headache.</p></td></tr><tr><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>Encephalopathy (high-dose therapy and dose-</p><p>limiting).</p></td></tr><tr><td style="vertical-align:top"><p>not known</p></td><td style="vertical-align:top"><p>Muscular pain, status epilepticus, seizure,</p><p>grand mal seizure.</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>very common</p></td><td style="vertical-align:top"><p>Ocular&nbsp;&nbsp;&nbsp; toxicities,&nbsp;&nbsp;&nbsp; transient&nbsp;&nbsp;&nbsp; conjunctival</p><p>flushing&nbsp;&nbsp;&nbsp;&nbsp; and&nbsp;&nbsp;&nbsp;&nbsp; blurred&nbsp;&nbsp;&nbsp;&nbsp; vision;&nbsp;&nbsp;&nbsp;&nbsp; retinal haemorrhages.</p></td></tr><tr><td style="vertical-align:top"><p>not known</p></td><td style="vertical-align:top"><p>Neuroretinitis</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>very common</p></td><td style="vertical-align:top"><p>Hypotension, due to alcohol content of diluent</p><p>(high-dose therapy)</p></td></tr><tr><td style="vertical-align:top"><p>not known</p></td><td style="vertical-align:top"><p>Tachycardia, chest pain</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>very common</p></td><td style="vertical-align:top"><p>Phlebitis, hypotension</p></td></tr><tr><td style="vertical-align:top"><p>rare</p></td><td style="vertical-align:top"><p>Veno-occlusive disease (high-dose therapy).</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Respiratory,&nbsp;&nbsp;&nbsp; thoracic&nbsp;&nbsp;&nbsp; and mediastinal disorders</p></td><td style="vertical-align:top"><p>very common</p></td><td style="vertical-align:top"><p><em>Pulmonary toxicity<sup>1</sup>,interstitial fibrosis (with prolonged&nbsp;&nbsp; therapy&nbsp;&nbsp; and&nbsp;&nbsp; cumulative&nbsp;&nbsp; dose</em></p><p><em>&gt;&nbsp; &nbsp;1400&nbsp; &nbsp;mg/m<sup>2</sup>)&nbsp; &nbsp;Pneumonitis&nbsp; &nbsp;(for&nbsp; &nbsp;doses</em></p><p><em>&gt;450mg/m<sup>2</sup>).</em></p></td></tr><tr><td style="vertical-align:top"><p>rare</p></td><td style="vertical-align:top"><p><em>Interstitial fibrosis (with lower doses).</em></p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>very common</p></td><td style="vertical-align:top"><p><em>emetogenic potential: &gt;250 mg/m<sup>2</sup> high;</em></p><p><em><u>&lt;</u>250 mg/m<sup>2</sup> high-moderate</em></p></td></tr><tr><td style="vertical-align:top"><p>very common</p></td><td style="vertical-align:top"><p><em>Nausea and vomiting, severe; begins within 2-</em></p><p><em>4 h of administration and lasts for 4-6 h</em>.</p></td></tr><tr><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>Anorexia, constipation, diarrhoea, stomatitis.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>unknown</p></td><td style="vertical-align:top"><p>Gastrointestinal bleeding</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>Hepatotoxicity, reversible, delayed up to 60 days after administration (high-dose therapy and dose-limiting), manifested by:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bilirubin, reversible increase</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; alkaline&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; phosphatase,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reversible increase</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SGOT, reversible increase.</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>not known</p></td><td style="vertical-align:top"><p><em>extravasation hazard: vesicant</em></p></td></tr><tr><td style="vertical-align:top"><p>very common</p></td><td style="vertical-align:top"><p>Dermatitis with topical use improves with reduced concentration of compounded product, hyperpigmentation, transient, with</p><p>accidental skin contact.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>Alopecia, flushing (due to alcohol content of diluent; increased with administration times</p><p>&lt;1-2 h), injection site reaction.</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>not known</p></td><td style="vertical-align:top"><p>renal failure, azotemia, decrease in kidney volume</p></td></tr><tr><td style="vertical-align:top"><p>rare</p></td><td style="vertical-align:top"><p><em>Renal toxicity (for cumulative doses &lt;1,000</em></p><p><em>mg/m<sup>2</sup>).</em></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Reproductive&nbsp;&nbsp;&nbsp; system&nbsp;&nbsp;&nbsp; and breast disorders</p></td><td style="vertical-align:top"><p>rare</p></td><td style="vertical-align:top"><p>Gynecomastia.</p></td></tr><tr><td style="vertical-align:top"><p>not known</p></td><td style="vertical-align:top"><p>Infertility, teratogenesis.</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>MedDRA&nbsp;&nbsp;&nbsp; system&nbsp;&nbsp;&nbsp; organ class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reactions</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Clinically important side effects are in <em>italics</em></p></td></tr><tr><td style="vertical-align:top"><p>General&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; disorders&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and administration site conditions</p></td><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>Burning sensation at injection site</p></td></tr></tbody></table><p><sup>1</sup>Pulmonary toxicity is also manifested as pneumonitis and interstitial lung disease in post- marketing experience</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u> Myelosuppression</p><p>Myelosuppression is very common and begins 7-14 days of administration with recovery 42-56 days of administration. The myelosuppression is dose and cumulative dose related, and often biphasic. Thrombocytopenia is generally more pronounced than leukopenia, but both are dose-limiting adverse effects. Anaemia is common but is usually less pronounced.</p><p>Eye disorders</p><p>&nbsp;</p><p>&nbsp;</p><p>Rapid intravenous infusion may cause conjunctival bleeding within 2 hours, lasting approximately 4 hours.</p><p>Respiratory, thoracic and mediastinal disorders</p><p>Pulmonary fibrosis (with fatal outcome), pulmonary infiltration</p><p>Pulmonary toxicity has been observed in up to 30% of patients. In cases where pulmonary toxicity started early (within 3 years of treatment), pulmonary infiltrates and/or pulmonary fibrosis occurred, some of which were fatal. The patients were between 22 months and 72 years old. Risk factors include smoking, respiratory disease, existing radiographic abnormalities, sequential or concomitant thoracic radiation, as well as combination with other active substances that can cause lung damage. The incidence of adverse reactions is probably dose-related; cumulative doses of 1200-1500 mg/m2 have been associated with an increased likelihood of pulmonary fibrosis. During treatment, lung function tests (FVC, DLCO) should be performed regularly. Patients showing a baseline value of &lt;70% of expected forced vital capacity or carbon monoxide diffusion capacity in these tests are at particular risk.</p><p>In patients having received carmustine in childhood or adolescence, cases of extremely delayed-onset pulmonary fibrosis (up to 17 years after treatment) have been described.</p><p>Long-term follow-up observation of 17 patients who survived brain tumours in childhood showed that 8 of them succumbed to pulmonary fibrosis. Two of these 8 fatalities occurred within the first 3 years of treatment and 6 of them occurred 8-13 years after treatment. The median age of patients who died on treatment was 2.5 years (1-12 years), the median age of long-term survivors on treatment was 10 years (5-16 years). All patients younger than 5 years of age at the time of treatment died from pulmonary fibrosis; neither the carmustine dose nor an additional vincristine dose or spinal radiation had any influence on the fatal outcome.</p><p>All remaining survivors available for follow-up were diagnosed with pulmonary fibrosis. Use of carmustine in children and adolescents &lt; 18 years is contraindicated, see section 4.3.</p><p>Pulmonary toxicity also manifested in the post-marketing phase as pneumonitis and interstitial lung disease. Pneumonitis is seen for doses &gt; 450 mg/m<sup>2</sup> and interstitial lung disease is seen with prolonged therapy and cumulative dose &gt; 1,400 mg/m<sup>2</sup>.</p><p>Emetogenic potential</p><p>The emetogenic potential is high at doses &gt; 250 mg/m<sup>2</sup> and high to moderate in doses</p><p>&le; 250 mg/m<sup>2</sup>. Nausea and vomiting are severe and begins within 2-4 h of administration and lasts for 4-6 h.</p><p>Renal toxicity</p><p>Renal toxicity is rare, but occurs for cumulative doses &lt; 1,000 mg/m<sup>2</sup>. Renal changes with decreased kidney volume, progressive azotemia, and renal failure have been reported after high cumulative doses and after long term therapy with carmustine and related nitrosoureas. Renal impairment was also occasionally observed after low total doses.</p><p><u>Reporting of suspected adverse reaction</u></p><p><span style="text-align:unset">Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed stated below:</span></p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><strong>To report any side effect(s):</strong><br />The National Pharmacovigilance Centre (NPC):<br />Fax: +966-11-205-7662<br />SFDA Call Center: 19999<br />E-mail: npc.drug@sfda.gov.sa<br />Website: https://ade.sfda.gov.sa</td></tr></tbody></table><p><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="_x0000_s1026" type="#_x0000_t202" style='position:absolute;
  left:0;text-align:left;margin-left:120.25pt;margin-top:63.15pt;width:386.9pt;
  height:130.95pt;z-index:-15727616;mso-wrap-distance-left:0;
  mso-wrap-distance-right:0;mso-position-horizontal-relative:page' filled="f"
  strokeweight=".48pt">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='margin-top:1.0pt;margin-right:0in;margin-bottom:
     0in;margin-left:5.35pt;margin-bottom:.0001pt'><b style='mso-bidi-font-weight:
     normal'>To<span style='letter-spacing:-.05pt'> </span>report<span
     style='letter-spacing:-.05pt'> </span>any<span style='letter-spacing:-.15pt'>
     </span>side<span style='letter-spacing:-.1pt'> </span>effect(s):<o:p></o:p></b></p>
     <p class=MsoBodyText style='margin-top:5.7pt;margin-right:0in;margin-bottom:
     0in;margin-left:5.35pt;margin-bottom:.0001pt'>National<span
     style='letter-spacing:-.1pt'> </span>Pharmacovigilance<span
     style='letter-spacing:-.05pt'> </span>Center<span style='letter-spacing:
     -.1pt'> </span>(NPC)<o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:6.0pt;margin-right:0in;margin-bottom:
     0in;margin-left:23.4pt;margin-bottom:.0001pt;text-indent:-18.05pt;
     mso-list:l0 level1 lfo1;tab-stops:23.35pt 23.4pt'><![if !supportLists]><span
     style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
     Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
     </span></span></span><![endif]><span dir=LTR></span>Fax: +966-11-205—6762<o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:5.95pt;margin-right:0in;margin-bottom:
     0in;margin-left:23.4pt;margin-bottom:.0001pt;text-indent:-18.05pt;
     mso-list:l0 level1 lfo1;tab-stops:23.35pt 23.4pt'><![if !supportLists]><span
     style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
     Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
     </span></span></span><![endif]><span dir=LTR></span>Call<span
     style='letter-spacing:.1pt'> </span>NPC<span style='letter-spacing:-.1pt'>
     </span>at +966-11-2038222,<span style='letter-spacing:-.05pt'> </span>Exts:2317-<span
     style='letter-spacing:-.15pt'> </span>2356 – 2353 – 2354 –<span
     style='letter-spacing:-.1pt'> </span>2334 –<span style='letter-spacing:
     -.1pt'> </span>2340<o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:6.0pt;margin-right:0in;margin-bottom:
     0in;margin-left:23.4pt;margin-bottom:.0001pt;text-indent:-18.05pt;
     mso-list:l0 level1 lfo1;tab-stops:23.35pt 23.4pt'><![if !supportLists]><span
     style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
     Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
     </span></span></span><![endif]><span dir=LTR></span>Toll<span
     style='letter-spacing:-.05pt'> </span>free phone:<span style='letter-spacing:
     -.1pt'> </span>8002490000<o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:5.95pt;margin-right:0in;margin-bottom:
     0in;margin-left:23.4pt;margin-bottom:.0001pt;text-indent:-18.05pt;
     mso-list:l0 level1 lfo1;tab-stops:23.35pt 23.4pt'><![if !supportLists]><span
     style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
     Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
     </span></span></span><![endif]><span dir=LTR></span>E-mail:<span
     style='letter-spacing:-.1pt'> </span><a href="mailto:npc.drug@sfda.gov.sa"><span
     style='color:windowtext;text-decoration:none;text-underline:none'>npc.drug@sfda.gov.sa</span></a><o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:5.95pt;margin-right:0in;margin-bottom:
     0in;margin-left:23.4pt;margin-bottom:.0001pt;text-indent:-18.05pt;
     mso-list:l0 level1 lfo1;tab-stops:23.35pt 23.4pt'><![if !supportLists]><span
     style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
     Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
     </span></span></span><![endif]><span dir=LTR></span>Website:<span
     style='letter-spacing:-.1pt'> </span><a href="http://www.sfda.gov.sa/npc"><span
     style='color:windowtext;text-decoration:none;text-underline:none'>www.sfda.gov.sa/npc</span></a><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The main symptom of intoxication is myelosuppression. In addition, the following serious side effects may occur:</p><p>Liver necrosis, interstitial pneumonitis, encephalomyelitis.</p><p>A specialized antidote is not available. There are no known myelo-protective substances. Bone marrow transplantation could be an effective measure</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antineoplastic agents, alkylating agents, nitrosoureas, ATC code: L01AD01</p><p><u>Mechanism of action</u></p><p>Carmustine (1,3-bis (2-chloroethyl) -1-nitrosourea) is a cell-cycle phase nonspecific antineoplastic agent of the nitrosourea type, which exerts tumor cytotoxicity via multiple mechanisms. As an alkylating agent, it can alkylate reactive sites on nucleoproteins, thus interfering with DNA and RNA synthesis and DNA repair. It is able to form interstrand crosslinks in DNA, which prevents DNA replication and transcription. In addition, carmustine is known to carbamoylate lysine residues on proteins causing irreversible inactivation of enzymes including glutathione reductase. The carbamoylating activity of carmustine is generally considered less significant than the alkylating activity in its action on tumours, but carbamoylation may serve to inhibit DNA repair.</p><p><u>Pharmacodynamic effects</u></p><p>The antineoplastic and toxic activities of carmustine may be due to its metabolites. Carmustine and related nitrosoureas are unstable in aqueous solutions and degrade spontaneously to reactive intermediates that are capable of alkylation and carbamoylation. The alkylating intermediates are believed to be responsible for the antitumor effect of carmustine. However, opinion is divided over the role of the carbamoylating intermediates as mediators of the biological effects of the nitrosoureas. On one hand, their carbamoylating activity was reported to contribute to the cytotoxic properties of their parent drugs by inhibiting DNA repair enzymes. On the other hand, it has been speculated that the carbamoylating species may mediate some of toxic effects of carmustine.</p><p>Carmustine crosses the blood-brain barrier readily because of its lipophilic nature. Paediatric population</p><p>Carmustine should not be used in children and adolescents due to high risk of pulmonary toxicity.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Distribution</u></p><p>Intravenously administered Carmustine is rapidly degraded, with no drug intact detectable after 15 minutes. Because of the good lipid solubility and the lack of ionization at the physiological pH, Carmustine is very well transferred through the blood-brain barrier. Levels of radioactivity in the CSF are at least 50% higher than those measured concurrently in plasma.</p><p>The kinetic of carmustine in humans is characterized by a two-chamber model. After the intravenous infusion over 1 hour, the carmustine-plasma level drops in a biphasic manner. The half life &alpha; accounts to 1-4 minutes and the half life &beta; accounts to 18-69 minutes.</p><p><u>Biotransformation</u></p><p>It is presumed that the metabolites of carmustine causes its antineoplastic and toxic activity.</p><p><u>Elimination</u></p><p>Approximately 60-70% of a total dose is excreted in the urine in 96 hours and about 10% as respiratory CO2. The fate of remain 20-30% is undetermined.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Carmustine was embryotoxic and teratogenic in rats and embryotoxic in rabbits at dose levels equivalent to the human dose. Carmustine affected the fertlility of male rats at doses slightly higher than the human dose. Carmustine, at clinically relevant dose levels, was carcinogenic in rats and mice with a marked increase in the incidence of tumours.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Powder</u></p><p>No excipients</p><p><u>Solvent</u></p><p>Ethanol, anhydrous</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Compatibility/ Incompatibility with Containers</u></p><p>The solution for infusion is unstable in polyvinyl chloride containers. The carmustine solution can be administered from glass bottles or polypropylene container only.</p><p>This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Unopened vial
3 years when stored in a refrigerator (2°C-8°C) protected from light. 
After reconstitution and dilution
After reconstitution as recommended, carmustine is stable for 24 hours under refrigeration (2°C - 8°C) in glass container.
The reconstituted solution further diluted with 500 ml sodium chloride for injection or 5% glucose for injection, in glass or polypropylene containers, results in a solution which should be utilized within 4 hours at room temperature and be protected from light. These solutions are also stable for 24 hours under refrigeration (2°C-8°C) and an additional 3 hours at room temperature protected from light.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store and transport refrigerated (2&deg;C &ndash; 8&deg;C).</p><p>Keep the vials in the outer carton in order to protect from light.</p><p>Alternatively, Carmustine can be transported&nbsp;&nbsp; at&nbsp;&nbsp; 2&deg;C&nbsp;&nbsp; to&nbsp;&nbsp; 8&deg;C.&nbsp;&nbsp; By&nbsp;&nbsp; following the recommended storage conditions it is possible to avoid any decomposition of the unopened vial until the date of expiry mentioned on the packaging.</p><p>The storage of carmustine at 27&deg;C or higher temperature can lead to liquefaction of the substance, since carmustine has a low melting point (ca. 30.5&deg;C to 32.0&deg;C).</p><p>An indication of the decomposition is the appearance of an oil film at the bottom of the vial. This medicine should not be used any further. For verification, hold the vial in bright light.</p><p>For storage conditions after reconstitution and further dilution of the medicinal product see section 6.3</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Powder</u></p><p>Type I amber glass vial (30 ml) with a dark grey bromobutyl rubber stopper and sealed with a polypropylene cap.</p><p><u>Solvent</u></p><p>Type I clear glass vial (5 ml) with a grey bromobutyl rubber stopper and sealed with a polypropylene cap.</p><p>One pack contains one vial with 100 mg of powder for concentrate for solution for infusion and one vial with 3 ml solvent.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>IMPORTANT NOTE:</strong></p><p>The lyophilized dosage formulation contains no preservative and is not intended as multiple dose vial. Reconstitution and further dilutions should be carried out under aseptic conditions.</p><p>The medicinal product is for single use only.</p><p><u>Reconstitution and dilution for each vial of the powder for concentrate for solution</u> <u>for infusion should be prepared as follows</u></p><p>Dissolve carmustine (100 mg powder) with 3 ml of the supplied sterile solvent and then aseptically add 27 ml of sterile water for injection to the alcohol solution. The 30 ml stock solution needs to be mixed thoroughly.</p><p>Each ml of the reconstituted solution will contain 3.3 mg of carmustine in 10% ethanol and have a pH of 5.6 to 6.0.</p><p>Reconstitution, as recommended, results in a clear, colourless solution.</p><p>The 30 ml stock solution is to be diluted immediately by adding the 30 ml stock solution to either 500 ml with sodium chloride 9 mg/ml (0.9%) solution for injection, or 500 ml with 5% glucose solution for injection.</p><p>The reconstituted and diluted solution ( i.e. the ready-to-use solution) must be given intravenously and should be administered by i.v. drip over 1-2 hours.</p><p>Infusion of Carmustine over shorter periods of time may produce intense pain and burning at the site of injection.</p><p>NOTE: Reconstituted vials stored under refrigeration should be examined for crystal formation prior to use. If crystals are observed, they may be redissolved by warming the vial to room temperature with agitation.</p><p>Carmustine has a low melting point (approximately 30.5-32.0<sup>o</sup>C or 86.9-89.6<sup>o</sup>F). Exposure of this drug to this temperature or above will cause the drug to liquefy and appear as an oil film in the bottom of the vials. This is a sign of decomposition and vials should be discarded.</p><p>These active substances occur in the environment. Any unused medicinal product or waste material should be disposed in accordance with local requirements.</p><p>Guidelines for the safe handling and disposal of antineoplastic agents must be observed.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Emcure Pharmaceuticals Limited (Oncology Division)
Plot no. P 2, I.T.B.T Park, Phase II, MIDC, Hinjawadi, Pune, India

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                June 2023 
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>